Relay Therapeutics, Inc. (RLAY) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$19.24

From 52W high−9.20%

Volume10.02M

Market cap$4.13B

P/E (TTM)—

P/S (TTM)398.9x

Div yield—

Key dataSep 18, 2026

Open

$19.24

From 52W high

−9.20%

Volume

10.02M

Market cap

$4.13B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.3x

P/E (TTM)

—

RSI (14)

47.1

MomentumView details →

1D Return

−1.82%

YTD Return

+123.29%

SummaryUpdated Jun 1, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company founded in 2015 and headquartered in Cambridge, Massachusetts. Originally incorporated as Allostery, Inc., the company changed its name to Relay Therapeutics in December 2015 and went public in July 2020. Relay focuses on transforming drug discovery through computational approaches, with an emphasis on developing small molecule therapeutics for targeted oncology and genetic diseases.

Ask drillr about Relay Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.3x

EV/Sales

313.9x

P/S (TTM)

398.9x

P/B (TTM)

4.6x

ProfitabilityView details →

Gross Margin

−566.59%

Net Margin

−2763.64%

EBITDA Margin

−2771.78%

ROE (TTM)

−32.14%

ROA (TTM)

−29.57%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

+23.86%

EPS YoY

+19.49%

FCF YoY

+19.02%

Revenue CAGR 3Y

+123.20%

EPS CAGR 3Y

+31.78%

EBITDA YoY

+11.42%

MomentumView details →

1D Return

−1.82%

YTD Return

+123.29%

1Y Return

+305.36%

RSI (14)

47.1

vs 50D SMA

−2.21%

vs 200D SMA

+40.05%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

18.27x

Quick Ratio

18.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.41

EPS Surprise

−4.84%

Beats (12Q)

6/12

Next Q EPS Est

−$0.40

Avg Surprise (4Q)

−3.98%

Rev Surprise

−63.54%

Financials snapshotView financials →

Revenue (TTM)

10.35M

Net Income (TTM)

−286.04M

Op. CF (TTM)

−212.21M

Next earningsNov 5, 2026 →

Latest newsMore news →

Relay Therapeutics, Inc. reported a second-quarter loss of $0.41 per share, in line with the Zacks Consensus Estimate and unchanged from the year-ago quarter.45d ago

Similar companies

Amylyx Pharmaceuticals, Inc.AMLX AbCellera Biologics Inc.ABCL Ocumension Therapeutics01477.HK 华恒生物688639.SH Telix Pharmaceuticals LimitedTLX TransThera Sciences (Nanjing) Inc.02617.HK Find similar companies →

Latest newsMore news →

Relay Therapeutics, Inc. reported a second-quarter loss of $0.41 per share, in line with the Zacks Consensus Estimate and unchanged from the year-ago quarter.45d ago